止血产品市场规模、份额及成长分析（按产品、应用、最终用途及地区）－2025 年至 2032 年产业预测

预计止血产品市场规模将在 2023 年达到 16.9 亿美元，并从 2024 年的 17.8 亿美元增长到 2032 年的 27.4 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.5%。

在医疗意识不断提高和医疗技术不断进步的推动下，全球止血产品市场正在持续成长。这些产品对于控製手术和创伤期间的出血以及治疗出血性疾病至关重要，由于人口老化以及慢性疾病和外科手术的增加，对这些产品的需求正在增长。此外，新兴市场医疗保健基础设施的改善也进一步推动了市场扩张。持续的研究和开发正在带来创新、更安全、更有效率的产品。然而，这些产品的监管障碍和高成本对市场成长构成了挑战。儘管存在这些障碍，但随着医疗保健标准和技术创新的发展，市场仍有望继续发展。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

止血产品市场规模：依产品及复合年增长率（2025-2032）

• 市场概览
• 局部止血
  • 胶原蛋白
  • 氧化再生纤维素
  • 明胶
  • 多醣
• 点滴止血
  • 捐献血液中的浓缩血小板
  • 血液来源的 FVIII
  • 新鲜冰冻血浆
  • 凝血酶原复合物
• 高级止血
  • 液体止血剂
  • 凝血酶
  • 纤维蛋白
  • 合成密封胶

止血产品市场规模：依应用与复合年增长率（2025-2032）

• 市场概览
• 创伤
• 外科手术
• 血友病
• 心肌梗塞
• 中风
• 血栓症

止血产品市场规模：依最终用途及复合年增长率（2025-2032）

• 市场概览
• 医院
• 门诊手术中心
• 其他的

止血产品市场规模：依地区及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• CSL Behring（Australia）
• Haemonetics Corporation（USA）
• Octapharma AG（Switzerland）
• Baxter International Inc.（USA）
• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• Becton, Dickinson and Company（USA）
• Medtronic plc（Ireland）
• Siemens Healthineers AG（Germany）
• Abbott Laboratories（USA）
• Roche Holding AG（Switzerland）
• Thermo Fisher Scientific Inc.（USA）
• Grifols, SA（Spain）
• Instrumentation Laboratory（Werfen）（USA）
• Stago Group（France）
• Sysmex Corporation（Japan）
• Siemens Healthineers AG（Germany）
• Danaher Corporation（USA）
• LivaNova PLC（UK）
• CryoLife, Inc.（USA）

结论和建议

Hemostasis Products Market size was valued at USD 1.69 billion in 2023 and is poised to grow from USD 1.78 billion in 2024 to USD 2.74 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The global hemostasis products market is experiencing consistent growth, fueled by heightened awareness and medical technology advancements. Essential for controlling bleeding during surgeries, trauma, and managing bleeding disorders, the demand for these products is amplified by an aging population and an increase in chronic diseases and surgical procedures. Additionally, improvements in healthcare infrastructure in developing regions are further propelling market expansion. Ongoing research and development are introducing innovative, safer, and more efficient hemostasis products. Nevertheless, regulatory hurdles and the high costs associated with these products present challenges to market growth. Despite these obstacles, the market is set for continued progress as healthcare standards and technological innovations evolve.

Top-down and bottom-up approaches were used to estimate and validate the size of the Hemostasis Products market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Hemostasis Products Market Segments Analysis

Global Hemostasis Products Market is segmented by Products, Application, End Use and region. Based on Products, the market is segmented into Topical Hemostasis, Infusible Hemostasis and Advanced Hemostasis. Based on Application, the market is segmented into Trauma, Surgery, Hemophilia, Myocardial Infarction, Stroke and Thrombosis. Based on End Use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Hemostasis Products Market

The Hemostasis Products market is significantly driven by innovations that focus on the development of safer and more environmentally friendly hemostatic solutions, including advanced agents and devices. These advancements not only enhance the management of bleeding complications and surgical processes but also contribute to better patient outcomes. As these improved products gain traction, they are stimulating growth within the market, leading to increased demand for effective hemostatic solutions. The ongoing emphasis on safety and effectiveness in hemostasis products plays a crucial role in shaping the future of medical practices related to bleeding control and surgical interventions.

Restraints in the Hemostasis Products Market

A significant challenge in the hemostasis products market is the high cost of these items. The elevated prices can limit accessibility for healthcare facilities with constrained budgets, as well as for patients in various regions. This financial barrier may impede the widespread adoption of advanced hemostasis solutions, ultimately restricting their market penetration. As a result, the impact on patient care could be substantial, as many healthcare providers may struggle to incorporate these critical products into their treatment protocols due to budgetary constraints, leading to disparities in the quality of care available to patients.

Market Trends of the Hemostasis Products Market

The Hemostasis Products market is witnessing a notable trend toward minimally invasive techniques, driven by a collective demand from healthcare providers and patients for less invasive solutions to manage bleeding during surgical procedures. This shift is propelling the development of advanced hemostasis products that minimize tissue damage, streamline recovery times, and enhance overall patient outcomes. As these techniques gain popularity, they offer increased patient comfort and shorter hospital stays, aligning perfectly with the healthcare industry's broader focus on value-based care. Consequently, manufacturers are innovating rapidly to meet these evolving needs, making the market poised for substantial growth.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hemostasis Products Market Size by Products & CAGR (2025-2032)

• Market Overview
• Topical Hemostasis
  • Collagen
  • Oxidized Regenerated Cellulose
  • Gelatin
  • Polysaccharide
• Infusible Hemostasis
  • Platelet Concentrates from Donor Blood
  • FVIII Derived from Blood
  • Fresh Frozen Plasma
  • Prothrombin Complex
• Advanced Hemostasis
  • Flowable
  • Thrombin
  • Fibrin
  • Synthetic Sealants

Global Hemostasis Products Market Size by Application & CAGR (2025-2032)

• Market Overview
• Trauma
• Surgery
• Hemophilia
• Myocardial Infarction
• Stroke
• Thrombosis

Global Hemostasis Products Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Others

Global Hemostasis Products Market Size & CAGR (2025-2032)

• North America (Products, Application, End Use)
  • US
  • Canada
• Europe (Products, Application, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Products, Application, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Products, Application, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Products, Application, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haemonetics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Instrumentation Laboratory (Werfen) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stago Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LivaNova PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CryoLife, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations